Macrophage migration inhibitory factor predicts an unfavorable outcome after transarterial chemoembolization for hepatic malignancies

• Main Authors: Theresa H. Wirtz (Author), Sven H. Loosen (Author), Max Schulze‐Hagen (Author), Joao Gorgulho (Author), Jennis Kandler (Author), Markus Joerdens (Author), Münevver Demir (Author), Raphael Mohr (Author), Philipp Bruners (Author), Christiane Kuhl (Author), Christian Trautwein (Author), Marie‐Luise Berres (Author), Frank Tacke (Author), Tom Luedde (Author), Christoph Roderburg (Author)
• Format: Book
• Published: Wiley, 2021-09-01T00:00:00Z.
• Subjects: article
• Online Access: Connect to this object online.

Abstract Transarterial chemoembolization (TACE) is a therapeutic option for patients with intermediate‐stage hepatocellular carcinoma (HCC) or metastatic liver cancers. Identifying those patients who particularly benefit from TACE remains challenging. Macrophage migration inhibitory factor (MIF) rep...